<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01803568</url>
  </required_header>
  <id_info>
    <org_study_id>2011/882</org_study_id>
    <nct_id>NCT01803568</nct_id>
  </id_info>
  <brief_title>Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU</brief_title>
  <acronym>MyoGlu</acronym>
  <official_title>Skeletal Muscles, Myokines and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian School of Sport Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normal glucose uptake and metabolism in skeletal muscles are essential to keep blood glucose&#xD;
      within normal range and hence, insulin resistance (possibly mediated by inflammatory&#xD;
      processes) in skeletal muscle is a major pathogenic factor in type 2 diabetes. Physical&#xD;
      activity seems to be of essential importance in the prevention and treatment of type 2&#xD;
      diabetes. Myokines are proteins secreted from skeletal muscle that can execute important&#xD;
      biological functions locally in the muscle (paracrine) or in other organs like the brain,&#xD;
      heart and pancreas (endocrine). Evidence suggest that several interleukines and other&#xD;
      cytokines are secreted by skeletal muscles. In the present project, the investigators will&#xD;
      explore the relation between secreted myokines from muscle cells, insulin resistance and&#xD;
      glucose metabolism before and after 12 weeks of exercise intervention. Subjects with normal&#xD;
      as well as impaired glucose metabolism will be included in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in gene expression changes in skeletal and adipose tissue</measure>
    <time_frame>Baseline and after 12 weeks, and before, 0 hr and 2 hours after acute exercise</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in plasma/serum levels of selected proteins</measure>
    <time_frame>Baseline and after 12 weeks, and before, 0 hr and 2 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin sensitivity</measure>
    <time_frame>Before and after 12 weeks of exercise</time_frame>
    <description>Insulin sensitivity will be measured using the euglycaemic hyperinsulinaemic clamp technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline from maximal oxygen uptake VO2 max</measure>
    <time_frame>Before and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in muscle strength</measure>
    <time_frame>Before and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body composition</measure>
    <time_frame>Before and after 12 weeks</time_frame>
    <description>Body composition will be estimated with whole body MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in heart frequency</measure>
    <time_frame>Before and after 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Normoglycemia</condition>
  <condition>Myokine</condition>
  <arm_group>
    <arm_group_label>Exercise in normoglycaemic individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise in hyperglycaemic individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>12 weeks of exercise; 4 times pr week</description>
    <arm_group_label>Exercise in hyperglycaemic individuals</arm_group_label>
    <arm_group_label>Exercise in normoglycaemic individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age 40-65 years&#xD;
&#xD;
          -  Nordic ethnicity&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
               1. Either (participants with impaired glucose metabolism): Body Mass Index (BMI)&#xD;
                  27-32 kg/m2 and abnormal glucose metabolism, defined as:&#xD;
&#xD;
                  i. impaired fasting glucose (FPG ≥ 5.6 mmol/L) ii. impaired glucose tolerance (2&#xD;
                  h PG ≥7.8 mmol/L) iii. type 2 diabetes (no medication, HbA1c ≤7.5%)&#xD;
&#xD;
               2. Or (controls): BMI 19-25 kg/m2 and normal glucose metabolism and no first degree&#xD;
                  relatives with type 2 diabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects having type 1 diabetes or medically treated type 2 diabetes.&#xD;
&#xD;
          2. Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg at screening&#xD;
&#xD;
          3. Significant hematological or renal disease or chronic renal impairment, GFR&lt; 50&#xD;
             ml/min.&#xD;
&#xD;
          4. Significant liver disease or ALAT &gt;3x UNL.&#xD;
&#xD;
          5. Chronic inflammatory disease in active phase or long-term use of corticosteroids last&#xD;
             3 months.&#xD;
&#xD;
          6. Use of anti-diabetic agents, lipid lowering drugs, antihypertensive medication, ASA or&#xD;
             any other drug not deemed suitable by the study physician.&#xD;
&#xD;
          7. Mental condition (psychiatric or organic cerebral disease), drug or alcohol abuse&#xD;
             rendering the subject unable to understand the nature, scope and possible consequences&#xD;
             of the study.&#xD;
&#xD;
          8. BMI outside inclusion criteria.&#xD;
&#xD;
          9. Smoker&#xD;
&#xD;
         10. Any medical or other condition that in the judgment of the investigator would&#xD;
             jeopardize the subject's safety or evaluation of the intervention for efficacy and&#xD;
             safety&#xD;
&#xD;
         11. Exercising regularly (&gt;1 times pr week)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kåre I Birkeland, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian A Drevon, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2013</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Kåre Inge Birkeland</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Myokine</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Exercise</keyword>
  <keyword>Skeletal muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

